Resection improves survival rate in advanced melanoma cases

04/16/2013 | SkinAndAllergyNews.com

Patients with advanced melanoma treated with surgical resection along with the drug ipilimumab had a 5-year melanoma-specific survival rate of 51% and a median overall survival duration of 60 months, according to researchers at the John Wayne Cancer Institute in Santa Monica, Calif. A 2012 study found a 7% survival rate for advanced melanoma patients treated with systemic medical therapy alone.

View Full Article in:

SkinAndAllergyNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY